Halozyme Therapeutics, Inc.
HALO
Rangering i aksjer
#1550
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San... Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.
Aksjekurs
$123.66
Markedsverdi
$14.04B
Endring (1 dag)
-0.57%
Endring (1 år)
84.90%
Land
US
Handel Halozyme Therapeutics, Inc. (HALO)
Kategori
Healthcare
P/E-forhold for Halozyme Therapeutics, Inc. (HALO)
P/E-forhold per October 2026 TTM: 33.19
Ifølge Halozyme Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 33.19. Ved slutten av 2023 hadde selskapet en P/E på 17.32.
P/E-forholdshistorikk for Halozyme Therapeutics, Inc. fra 2001 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 33.19 | 143.13% |
| 2024 | 13.65 | -21.15% |
| 2023 | 17.32 | -55.05% |
| 2022 | 38.52 | 174.31% |
| 2021 | 14.04 | -68.84% |
| 2020 | 45.07 | -227.22% |
| 2019 | -35.42 | 35.59% |
| 2018 | -26.13 | -159.52% |
| 2017 | 43.89 | -459.83% |
| 2016 | -12.20 | -82.10% |
| 2015 | -68.13 | 293.44% |
| 2014 | -17.32 | -14.52% |
| 2013 | -20.26 | 45.54% |
| 2012 | -13.92 | -71.79% |
| 2011 | -49.34 | 251.50% |
| 2010 | -14.04 | 60.96% |
| 2009 | -8.72 | -5.11% |
| 2008 | -9.19 | -58.44% |
| 2007 | -22.11 | -35.28% |
| 2006 | -34.17 | 395.28% |
| 2005 | -6.90 | -19.50% |
| 2004 | -8.57 | -97.66% |
| 2003 | -366.80 | 22.46% |
| 2002 | -299.53 | 132.99% |
| 2001 | -128.56 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 28.78 | -13.28% |
US
|
|
| -28.36 | -185.45% |
US
|
|
| -24.57 | -174.02% |
AU
|
|
| 30.33 | -8.61% |
NL
|
|
| - | - |
CH
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.